Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07289672

Food Limitations In Crohn's Disease and Ulcerative coliTis

The goal of this clinical trial is to increase the knowledge on what type of diet affects inflammation and how to better convay that information in patients with inflammatory bowel disease (IBD) and decrease selective eating in patients with IBD. The main questions it aims to answer are:

* will the use of calprotectin as a control for changes in inflammation decrease selective food choices? * will the use of a digital information tool increase quality of life (QoL) och decrease selctive eating patterns? * will a diet based on nordic food choices decrease inflammation and increase QoL?

Researchers will compare with IBD-patients in ordinary care.

Participants will eat a test diet during six weeks or go through a digital information tool.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Crohn Disease (CD) Colitis Colitis, Ulcerative Colonic Diseases Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases IBD (Inflammatory Bowel Disease) Inflammatory Bowel Diseases Intestinal Diseases Ulcerative Colitis (UC)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mag- och tarmmottagningen, Skåne university hospital

Malmö, 20502, Sweden

About this study

Patients with inflammatory bowel disease attending the out-patient clinic at Skåne university hospital with calprotectin 200-600 will be invited to participate in this diet intervention study. They will be divided into four arms with 35 patients in each, normal diet, test diets or diet with digital information tool.

The diet will be recorded at study start and end with a food diary for four days, as will health related quality of life. The patients clinical characteristics (demographics) and disease activity (diarrhoea frequency, blood in stools, abdominal pain, CRP and calprotectin) will be recorded.

The patients clinical characteristics (demographics) and disease activity (diarrhoea frequency, blood in stools, abdominal pain, CRP and calprotectin) will be recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ulcerative colitis and Crohn's disease
  • Calprotectin 200-600

Exclusion criteria

  • Non-active disease
  • solely procitis
  • Severe disease
  • past extensive bowel surgery
  • treatment with antibiotics (last month or present)
  • pregnancy
  • unability to understand spoken or written Swedish
  • Multimorbidity which aggrevate participation

Treatment and study plan

Diet

Other

Healthy nordic based food

Education

Other

Digital information tool/education on food in inflammatory bowel disease (IBD)

Primary outcomes

  1. Concentration of calproteictin

    Time frame: From enrollment until 6 weeks

Secondary outcomes

  1. Four days registrered food intake

    Time frame: At beginning and after 6 week

    Food intake will be registrered at beginning and after 6 week

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Registry information

Official study title

Förändrat Livsmedelsval Vid Inflammatorisk Tarmsjukdom

Acronym: FLIT

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 17, 2025
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.